A
Soleno Therapeutics, Inc. — Earnings Quality Grade A
SLNO · Healthcare
Strong financial health
Revenue
$190M
2025
Net Income
$21M
2025
Gross Margin
98.6%
Free Cash Flow
$47M
01
Screening Summary
8
Passed
1
Watch
0
Failed
—
M-Score
Management Signals
Source: SEC EDGAR 8-K Item 5.02, with exhibit links when available
02
Financial Trends
Revenue & Net Income ($B)
Margins (%)
03
18-Point Screening
01
Revenue Quality
—
A1DSO Change
Insufficient data
—
A2AR vs Revenue Growth
Insufficient data
—
A3Revenue vs CFFO
Insufficient data
02
Expense Quality
—
B1Inventory vs COGS
Insufficient data
—
B2CapEx vs Revenue
Insufficient data
!
B3SG&A Ratio
SG&A/Gross Profit = 70.4%, exceeds 70%
—
B4Gross Margin
Insufficient data
03
Cash Flow Quality
✓
C1CFFO vs Net Income
CFFO/NI = 2.24. Profits backed by cash
✓
C2Free Cash Flow
FCF $0.0B, FCF/NI = 2.24
✓
C3Accruals Ratio
Accruals ratio = -4.6%. Low accruals
✓
C4Cash vs Debt
Cash $0.3B covers debt $0.1B
04
Balance Sheet Health
✓
D1Goodwill + Intangibles
Goodwill+Intangibles $0.0B = 1% of equity. Manageable
✓
D2Leverage
Debt/EBITDA = 1.9x. Healthy
—
D3Soft Asset Growth
Insufficient data
—
D4Asset Impairment
No write-off data
05
Acquisition Risk
✓
E1Serial Acquirer FCF
FCF after acquisitions positive
✓
E2Goodwill Surge
Goodwill+Intangibles change -29% YoY. Normal
06
Manipulation Score
—
F1Beneish M-Score
Calculation error: float division by zero
05
Altman Z-Score
5.4
Safe Zone0 Distress1.102.605.0+ Safe
0.5222
Liquidity
-0.7651
Cumulative profit
0.0468
Operating efficiency
3.9583
Leverage
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25